Novo Nordisk's (NVO) investors are worried its competition ... Lilly's Zepbound overtook Novo's Wegovy as the leading obesity drug, according to the latest prescription data last month.

Novo Nordisk also highlighted the completion of its REDEFINE 2 trial for CagriSema, its next-generation obesity drug. The treatment ... for US approval of oral semaglutide 25 mg, with the ...

Novo Nordisk NOVO.B3.59%increase; green up pointing triangle said the Food and Drug Administration accepted its submission of a new drug application for a Wegovy pill to treat obesity amid a tense ...

Novo Nordisk A/S NVO is seeking FDA approval for the pill version of its obesity drug, Wegovy ... profile similar to once-weekly injectable semaglutide 2.4 milligram.” During the trial, adults ...

70. Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug semaglutide, sold under the brand names Ozempic and Wegovy.

April 14 (Reuters) - Danish drugmaker Novo Nordisk ... known as semaglutide, has given rise to concerns about unregulated, compounded and counterfeit medicines. Its weight-loss drug Wegovy also ...

Hims & Hers started prescribing compounded semaglutide, the active ingredient in Novo Nordisk's diabetes drug Ozempic and Wegovy, in May of 2024. The company has largely had to stop offering the ...

Novo Nordisk is partnering with online telehealth companies to sell a direct-to-consumer, lower cost version of its popular weight-loss drug Wegovy. The pharmaceutical company announced it would ...